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Cisplatin is a first-line chemotherapeutic for ovarian cancer, although chemoresistance limits treatment success. Apoptosis, an
important determinant of cisplatin sensitivity, occurs via caspase-dependent and -independent mechanisms. Activation of the protein
kinase Akt, commonly observed in ovarian tumours, confers resistance to ovarian cancer cells via inhibition of caspase-dependent
apoptosis. However, the effect of Akt on cisplatin-induced, caspase-independent apoptosis remains unclear. We show that in
chemosensitive ovarian cancer cells, cisplatin induces the mitochondrial release and nuclear translocation of apoptosis-inducing factor
(AIF), a mediator of caspase-independent apoptosis, and AIF-dependent apoptosis. Cisplatin failed to induce these effects in the
chemoresistant variant cells. Overexpression of AIF sensitised resistant cells to cisplatin-induced apoptosis. Finally, activation of Akt
attenuated the cisplatin-induced mitochondrial release and nuclear accumulation of AIF and apoptosis in chemosensitive cells,
whereas inhibition of Akt activity facilitated these effects and sensitised chemoresistant cells to AIF-dependent, cisplatin-induced
apoptosis. These results suggest that cisplatin-induced apoptosis proceeds, in part, via a caspase-independent mechanism involving
AIF, and that Akt activation confers resistance to cisplatin-induced apoptosis by blocking this pathway. These results provide insights
into the molecular mechanism of chemoresistance, and suggest that inhibition of Akt activity may represent a novel therapeutic
approach to the treatment of cisplatin-resistant ovarian cancer.
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Chemoresistance is a significant barrier to the successful treatment
of human ovarian cancer. While many factors affect the sensitivity
of cancer cells to chemotherapy, the regulation of a number of key
mediators of apoptosis is frequently altered in chemoresistant cells
(Asselin et al, 2001; Fraser et al, 2003; Dan et al, 2004).
Apoptosis-inducing factor (AIF) is a mitochondrial intermem-
brane flavoprotein that is released from the mitochondria and
translocates to the nucleus in response to specific death signals
(Susin et al,1 9 9 9 ;D a u g a set al, 2000). Nuclear AIF causes large-scale
DNA fragmentation and chromatin condensation in a caspase-
independent manner (Cregan et al, 2002), and recent studies have
shown that mitochondrial AIF release is regulated by p53 and the
Bcl-2 family (Cregan et al,2 0 0 2 ;M a c F a r l a n eet al, 2002; Kandasamy
et al,2 0 0 3 ;M a j e w s k iet al, 2004; Vyas et al,2 0 0 4 ) .
Akt (protein kinase B) mediates the cell survival action of
growth factors and cytokines in a variety of cell types and blocks
apoptosis induced by multiple apoptotic stimuli. It is a major
downstream target of phosphatidylinositol 3-OH-kinase (PI3K)
(Cheng et al, 2002; Franke et al, 2003; Fresno Vara et al, 2004).
Both PI3K and Akt are frequently activated and/or overexpressed
in human ovarian cancer (Fraser et al, 2003; Dan et al, 2004). Akt
activation promotes cell survival, suppresses apoptotic death and
regulates cis-platinum (II) diammine dichloride (CDDP) sensitivity
in human ovarian cancer cells (Asselin et al, 2001; Fraser et al,
2003; Dan et al, 2004).
We previously demonstrated that activated Akt is an important
regulator of both X-linked inhibitor of apoptosis protein and p53
levels after cisplatin (CDDP) challenge and that p53 mutational
status is a determinant of Akt-mediated chemoresistance (Fraser
et al, 2003; Dan et al, 2004). Recent data from our laboratory have
shown that p53 triggers the Akt-sensitive release of mitochondrial
Smac into the cytosol and induces apoptosis via a caspase-
dependent pathway (Yang et al, 2006). However, other groups have
reported that mitochondrial AIF translocation to the nucleus
induces caspase-independent apoptosis (Cregan et al, 2002).
Whether this process contributes to CDDP-induced apoptosis
and is regulated by Akt remain unclear.
In the current study, we demonstrate that CDDP-induced
mitochondrial AIF translocation to nucleus is a determinant of
chemosensitivity in ovarian cancer cells. Decreased mitochondrial
AIF release is one mechanism by which Akt-mediated chemore-
sistance occurs. Our results suggest that modulation of these key
cell fate regulators may be an effective means of overcoming
chemoresistance in human ovarian cancer.
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sMATERIALS AND METHODS
Reagents
Cells were cultured at 371C with 5% CO2 in RPMI (Roswell Park
Memorial Institute, Buffalo, NY, USA)-1640 (OV2008 and C13*) or
DMEM (Dulbecco’s modified Eagle’s medium)/F-12 (A2780s,
A2780cp; Invitrogen Inc., Burlington, ON, Canada). Medium
was supplemented with 10% fetal bovine serum, strepto-
mycin (100mgml
 1), penicillin (100Uml
 1), and fungizone
(0.625mgml
 1). Digitonin, CDDP, dimethyl sulphoxide, and
Hoechst 33258 were supplied by Sigma (Oakville, ON, Canada).
Apoptosis-inducing factor small inhibitory RNA was from Santa
Cruz Biotechnology (cat. no. sc-29193; Santa Cruz, CA, USA).
Negative control siRNA was from Dharmacon Inc. (Chicago, IL,
USA). Ribojuice siRNA transfection reagent was from Novagen
(San Diego, CA, USA). Adenoviral AIF cDNA and LacZ cDNA were
synthesised at the Neuroscience Research Institute, University of
Ottawa (Ottawa, ON, Canada). All adenovirus stock solutions were
CsCl purified. Primary antibodies were anti-AIF rabbit polyclonal
IgG (Santa Cruz Biotechnology), anti-actin mouse monoclonal IgG
(Cedarlane Laboratories Ltd, Burlington, ON, Canada), anti-Cox-4
mouse monoclonal IgG (Molecular Probes, Burlington, ON,
Canada), and anti-C23 mouse monoclonal IgG (Santa Cruz
Biotechnology). Horseradish peroxidase-conjugated anti-mouse
and anti-rabbit antibodies for western blot were obtained from
Bio-Rad (Hercules, CA, USA). Enhanced chemiluminescent rea-
gents were from Amersham Biosciences (Buckinghamshire, UK).
Cell culture
Chemosensitive cells (OV2008 and A2780s) and their resistant
variants (C13* and A2780cp, respectively) were cultured and
treated as reported previously (Fraser et al, 2003). Cells were
cultured in RPMI-1640 or DMEM/F12, respectively, containing
G418 (250mgml
 1; Invitrogen). All CDDP treatments were
performed in serum-free media.
C13* cells were stably transfected with pcDNA3.1-DN-Akt2 and
A2780s cells were stably transfected with pcDNA3-Myr-Akt2 in the
laboratory of Dr Jin Cheng (Moffatt Cancer Center, Tampa, FL,
USA) and maintained in RPMI-1640 or DMEM/F12, respectively,
each containing G418 (250mgml
 1; Invitrogen).
Adenovirus infection
Cells were infected with AIF adenoviral constructs as indicated in
the text. Infection with LacZ adenovirus was used to normalise the
total concentration of adenovirus in each treatment group.
Adenovirus infection efficiency was determined as reported
previously (Fraser et al, 2003).
Preparation of whole-cell lysates and subcellular fractions
Before fractionation, the cells were cultured and treated as above.
Following treatment, cells were washed with ice-cold phosphate-
buffered saline, left on ice for 10min, and then resuspended in
homogenisation buffer (250mM sucrose, 10mM KCl, 1.5mM MgCl2,
1m M Na-EDTA, 1mM Na-EGTA, 1mM dithiothreitol, 0.1mM
phenylmethylsulphonyl fluoride, and 10mM Tris-HCl (pH 7.4))
containing the proteinase inhibitor aprotinin (1mgml
 1). After 60
strokes in a Dounce homogeniser, the unbroken cells were spun
down at 30g for 5min. The nuclear and heavy mitochondrial
fractions were collected at 750g for 10min and at 14000g for
20min, respectively, from the supernatant. The nuclear fraction
was washed three times with the homogenisation buffer containing
0.01% NP-40.
Western blot analyses
Western blotting was performed as described previously (Fraser
et al, 2003). Membranes were incubated overnight at 41Ci n
primary antibodies (anti-AIF, 1:500; anti-actin, 1:2000; anti-Cox-
4, 1:1000; anti-LDH, 1:1000), followed by incubation with
horseradish peroxidase-conjugated anti-rabbit or anti-mouse
secondary antibody (1:2000) at room temperature for 1h.
Peroxidase activity was visualised with the enhanced chemilumi-
nescence kit. Results were scanned and analysed using Scion Image
software (Scion Inc.).
Assessment of apoptosis
After treatment, cells were harvested and the percentage of
apoptosis was determined by Hoechst 33258 staining
(12.5ngml
 1), as reported previously (Abedini et al, 2004). Cells
were counted with the counter ‘blinded’ to sample identity to avoid
experimental bias.
Statistical analyses
Results are presented as mean±s.e.m. of at least three independent
experiments. Data were analysed by two-way ANOVA and
Bonferroni post-test to test the differences between groups (PRISM
software version 3.0; GraphPad, San Diego, CA, USA). Statistical
significance was inferred at Po0.05.
RESULTS
CDDP induces nuclear translocation of mitochondrial AIF
and apoptosis in chemosensitive, but not chemoresistant,
ovarian cancer cells
To determine the relationship between subcellular AIF distribution
and CDDP sensitivity, chemosensitive ovarian cancer cells
(OV2008 and A2780s) and their resistant variants (C13* and
A2780cp, respectively) were cultured with different concentrations
of CDDP (24h; 0, 2.5, 5, and 10mM; dimethyl sulphoxide as
control). Mitochondrial and nuclear fractions were prepared and
AIF levels were determined by western blot. C23 and Cox-IV were
used as purity controls for mitochondria and nucleus, respectively.
As shown in Figure 1A, CDDP decreased mitochondrial and
increased nuclear AIF contents in OV2008 and A2780s cells but not
in C13* or A2780cp cells. Furthermore, the accumulation of AIF in
the nucleus of chemosensitive cells was associated with an increase
in the percentage of cells undergoing apoptosis, as measured by
evaluation of nuclear morphology by Hoechst 33258 nuclear
staining. However, CDDP failed to induce apoptosis in C13* or
A2780cp cells during CDDP treatment (Figure 1B).
In addition, we extended these concentration–response experi-
ments to include time-course studies. OV2008 and C13* cells were
treated with 10mM CDDP for different durations (0–24h). It was
observed that CDDP decreased mitochondrial AIF levels and
induced apoptosis in the chemosensitive ovarian cancer cells
(OV2008), but not in the resistant variant (C13*). These changes
were time-dependent (Figure 2). Taken together, these data
demonstrate that CDDP induces mitochondrial AIF translocation
and apoptosis in chemosensitive, but not chemoresistant, ovarian
cancer cells.
AIF is required for CDDP-induced apoptosis
To determine whether AIF is required for CDDP-induced
apoptosis, OV2008 cells were transfected with AIF or control
siRNA (0–400nM) for 48h and then treated with 10mM CDDP for
24h. Downregulation of AIF was confirmed by western blot
(Figure 3A and B). Apoptosis-inducing factor siRNA (200–400nM)
Regulation of mitochondrial AIF translocation by Akt
X Yang et al
804
British Journal of Cancer (2008) 98(4), 803–808 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
smarkedly decreased whole-cell AIF content, and these changes
significantly attenuated CDDP-induced apoptosis in these cells
(**Po0.01; Figure 3A). We extended this experiment to a single
concentration of AIF siRNA (200nM) and subcellular AIF levels
were measured by western blot. As shown in Figure 3B, 200nM AIF
siRNA significantly attenuated whole-cell AIF level as well as
mitochondrial and nuclear AIF content. The lower AIF content was
associated with decreased CDDP-induced apoptosis in OV2008
cells (***Po0.001).
We next determined whether an increased AIF level is sufficient
to sensitise resistant cells to CDDP-induced apoptosis. C13* cells
were infected with adenoviral AIF (MOI (multiplicity of in-
fection)¼0, 50, and 100; LacZ control) for 48h, followed by
incubation of CDDP (10mM) for 24h. Apoptosis-inducing factor
markedly sensitised the resistant cells to CDDP-induced apoptosis
in a concentration-dependent manner (***Po0.001; Figure 3C).
Taken together, these results demonstrate that AIF is an important
mediator of CDDP-induced apoptosis and that overexpression of
AIF is an effective means of overcoming chemoresistance in
ovarian cancer cells.
Akt inhibits CDDP-induced mitochondrial AIF
translocation to nucleus in ovarian cancer cells
Activation of Akt impairs the cellular stress response and
confers resistance to CDDP-induced apoptosis in tumour cells
(Dan et al, 2004). Moreover, we previously demonstrated that Akt
suppresses apoptotic cell death and regulates CDDP sensitivity in
ovarian cancer cells (Asselin et al, 2001; Fraser et al, 2003).
However, if and how Akt regulates CDDP-induced nuclear
translocation of mitochondrial AIF is unknown, as is the
involvement of this process in the regulation of chemosensitivity.
To determine if Akt regulates CDDP-induced AIF translocation,
chemosensitive ovarian cancer cells (A2780s) stably transfected
with constitutively active Akt2 (myristoylated wild-type Akt2;
A2780s-AAkt2) were cultured with different concentrations of
CDDP (0, 2.5, 5, and 10mM). In control-transfected cells (A2780s-
PMH6), CDDP decreased mitochondrial AIF level and increased
nuclear AIF contents, whereas these responses were absent in
A2780s-AAkt2 cells, suggesting that Akt activation suppresses
CDDP-induced nuclear translocation of mitochondrial AIF
(Figure 4A).
To further ascertain the role of Akt2 in the regulation of
mitochondrial AIF translocation in CDDP-induced apoptosis in
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Figure 1 CDDP induced mitochondrial AIF translocation to nucleus and apoptosis in chemosensitive, but not resistant, ovarian cancer cells.
Chemosensitive (OV2008, A2780s) and resistant (C13*, A2780cp) cells were treated with different concentrations of CDDP (0, 2.5, 5, and 10mM) for 24h.
CDDP decreased mitochondrial and increased nuclear AIF contents (A) as well as induced apoptosis (B) in a concentration-dependent manner in OV2008
and A2780s cells, but not C13* and A2780cp cells (**Po0.01, ***Po0.001). Cox-4 blots indicate mitochondrial loading. C23 was used as a loading control
for the nuclear fraction. The reciprocal blots demonstrate purity of the preparations. CDDP-induced apoptosis was assessed by Hoechst staining.
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Figure 2 CDDP induced mitochondrial AIF translocation (A) and
apoptosis (B) in a time-dependent manner in chemosensitive, but not
resistant, ovarian cancer cells. OV2008 and C13* cells were treated with
10mM CDDP for different durations (0–24h). CDDP induced decrease in
mitochondrial and increase in nuclear AIF contents in OV2008 cells in a
time-dependent manner, but not in C13* cells (*Po0.05, **Po0.01,
***Po0.001).
Regulation of mitochondrial AIF translocation by Akt
X Yang et al
805
British Journal of Cancer (2008) 98(4), 803–808 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sovarian cancer cells, we extended these observations with a
concentration–response (0, 2.5, 5, and 10mM) study using the
chemoresistant ovarian cancer cell line C13* and C13*-DNAkt2
cells, which are C13* cells stably transfected with dominant-
negative Akt2 (T308A, S473A). Western blotting analyses demon-
strated that downregulation of Akt2 facilitated a CDDP-induced
decrease in mitochondrial AIF content and an increase in nuclear
AIF level, and sensitised chemoresistant ovarian cancer cells to
CDDP-induced apoptosis (Figure 4B). These findings suggest that
Akt2 regulates CDDP-induced AIF translocation and is a
determinant of chemoresistance in ovarian cancer cells.
To confirm that AIF is involved in Akt-mediated chemoresis-
tance, we infected chemoresistant C13* cells with adenoviral HA-
DN-Akt (MOI¼80; LacZ control) in the presence or absence of
control or AIF siRNA (200nM). As shown in Figure 4C, AIF siRNA
markedly downregulated AIF content. Moreover, while expression
of DN-Akt sensitised the cells to CDDP-induced apoptosis
(Po0.001), downregulation of AIF significantly attenuated this
response, suggesting that AIF is downstream of Akt and that Akt-
mediated chemoresistance involves, in part, the disruption of AIF
function.
DISCUSSION
Mitochondrial membrane permeabilisation is considered to be one
of the initial events of the apoptotic process induced by
chemotherapeutic drugs. Opening of the mitochondrial permeability
transition pore, which is under the control of members of the Bcl-2
family, results in the permeabilisation of the outer mitochondrial
membrane and subsequent release of apoptogenic proteins such as
cytochrome c and Smac (Kuwana et al, 2002; Green, 2005). In the
present study, we have demonstrated that CDDP induced mito-
chondrial AIF translocation in chemosensitive ovarian cancer cells,
but not in their resistant variants, in a time- and concentration-
dependent manner, suggesting that AIF translocation may be a
determinant of CDDP-induced apoptosis. Downregulation of AIF by
siRNA conferred resistance to chemosensitive cells, suggesting that
AIF release is required for CDDP-induced apoptosis. While there is
evidence that AIF release is induced by a wide range of cellular
insults, including chemotherapeutic agents (Alfano et al, 2006;
Massard et al, 2006), our data represent, to our knowledge, the first
report directly demonstrating that mitochondrial AIF translocation
to nucleus is an important determinant of CDDP-induced apoptosis.
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Figure 3 Apoptosis-inducing factor is required for CDDP-induced apoptosis in ovarian cancer cells. (A) OV2008 cells were transfected with AIF siRNA
(0–400nM; 48h) and then treated with CDDP (10mM; 24h). Downregulation of AIF was confirmed by western blot. Downregulation of AIF significantly
attenuated CDDP-induced apoptosis in OV2008 cells (**Po0.01). (B) OV2008 cells were tranfected with 200nM AIF siRNA for 48h, followed by CDDP
treatment (10mM; 24h). Transfection of 200nM AIF siRNA decreased AIF content in whole cell and mitochondria and decreased AIF translocation to
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48h, followed by CDDP treatment (10mM; 24h; ***Po0.001).
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sCDDP-based chemotherapy is an important treatment modality,
and the development of chemoresistance is a major hurdle limiting
successful treatment. However, the molecular mechanisms under-
lying chemoresistance are poorly understood. It is well established
that CDDP induces cell death by activating death receptor- and
mitochondria-mediated apoptosis (Alfano et al, 2006; Massard
et al, 2006). Caspases are a family of cysteine proteases that have
been implicated as key effector molecules in the execution of
apoptotic cell death (Cryns and Yuan, 1998). Many of the
characteristic morphological and biochemical changes that occur
during apoptosis result from activation of caspases. More than 10
caspases have been identified. While some (e.g., caspase 8 and 10)
are involved in the initiation of apoptosis, others (e.g., caspase 3, 6,
and 7) execute cell death by destroying essential proteins.
Although caspases are important mediators of apoptosis, there
is accumulating evidence indicating the existence of caspase-
independent mechanisms of CDDP-induced cell apoptosis (Barton
et al, 2005). It has been reported that AIF mediates cell death
through a caspase-independent pathway (Cregan et al, 2002).
Mitochondrial AIF translocates to the nucleus following a death
stimulus and initiates nuclear condensation. Once the nucleus
condenses, this leads to large-scale chromatin fragmentation,
followed by cell death. In the present study, we found that AIF
nuclear translocation is also required for CDDP-induced apoptosis,
suggesting that apoptotic cell death induced by CDDP may also be
AIF-dependent. While these results are in agreement with those of
Henkels and Turchi (1999), they also represent, to our knowledge,
the first demonstration that AIF is required for CDDP-induced
apoptosis, and suggest that AIF may contribute to the observed
caspase-independent apoptosis induced by CDDP.
Akt is a major downstream effector of PI3K (Franke et al, 1995).
Akt promotes cell survival, suppresses apoptosis, and regulates
CDDP sensitivity in ovarian cancer cells (Asselin et al, 2001; Fraser
et al, 2003; Dan et al, 2004). In a previous study, we demonstrated
that Akt regulates Smac release and apoptosis by attenuating the
mitochondrial actions of p53 (Yang et al, 2006). Our present data
also show that mitochondrial AIF translocation to nucleus is
regulated by Akt during CDDP-induced apoptosis in ovarian
cancer, suggesting that activation of Akt promotes chemo-
resistance, in part, by attenuating CDDP-induced AIF transloca-
tion from mitochondria to nucleus. This result also suggests that
Akt may inhibit both caspase-dependent and -independent
apoptosis signalling pathways, thus providing a potential explana-
tion for the potent anti-apoptotic effects of this molecule.
The mechanisms by which Akt may regulate AIF nuclear trans-
location are not clear. Apoptosis-inducing factor does not contain
a consensus Akt phosphorylation site. As such, it is unlikely that
the observed effects of Akt on AIF are due to a direct interaction
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Figure 4 Akt regulates CDDP-induced mitochondrial AIF translocation and apoptosis in ovarian cancer cells. (A) Activated Akt2 inhibited mitochondrial
AIF translocation and CDDP-induced apoptosis. A2780s-PMH6 (control) and A2780s-AAkt2 (active Akt2) cells were treated with CDDP (0–10mM; 24h).
Compared with A2780s-PMH6 cells, A2780s-AAkt2 cells showed a significant suppression of CDDP-induced AIF translocation. Constitutively activated
Akt2 also reduced the sensitivity of A2780s cells to cisplatin-induced apoptosis (*Po0.05, ***Po0.001) expressing DN-Akt2 in response to CDDP. (B)
Inhibition of Akt2 sensitised C13* cells to CDDP (*Po0.05). (C) C13* cells were infected with DN-Akt (MOI¼80; LacZ control) in the presence or
absence of AIF siRNA (200nM). DN-Akt sensitised the cells to CDDP-induced apoptosis, which was attenuated by downregulation of AIF (***Po0.001).
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sbetween the molecules. Alternatively, Akt may act at the
mitochondria, directly attenuating the release of pro-apoptotic
proteins from the mitochondria to the cytoplasm. Akt is known to
phosphorylate and inactivate proteins, such as Bad, implicated in
mitochondrial pore formation, so it is possible that this plays a
significant role in mediating the anti-apoptotic effects of Akt.
Finally, we have previously demonstrated that Akt attenuates
translocation of p53 to the mitochondria (Yang et al, 2006), and
that mitochondrial p53 can directly stimulate the release of pro-
apoptotic proteins from the mitochondria. As such, it is possible
that the inhibition of nuclear AIF accumulation induced by Akt
activation is secondary to the inhibition of p53-dependent release
of AIF from the mitochondria. The precise mechanism underlying
this phenomenon is currently under investigation in our
laboratory.
In summary, we report here that translocation of AIF from
mitochondria to the nucleus is disrupted in chemoresistant cells,
relative to their sensitive counterparts, and that AIF is required for
CDDP-induced apoptosis. Furthermore, we have demonstrated
that failure to induce mitochondrial release and nuclear accumula-
tion of AIF may be an important determinant of resistance to
CDDP in ovarian cancer cells, and that Akt activation may confer
resistance, in part, through modulation of this pathway.
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